Kymera Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $3,741 | $25,650 | $10,287 | $47,885 |
Gross Profit | 1,741 | 23,750 | 8,787 | 47,020 |
EBITDA | -60,427 | -40,101 | -46,988 | -13,451 |
EBIT | -62,427 | -42,001 | -48,488 | -14,316 |
Net Income | -62,487 | -42,062 | -48,557 | -14,368 |
Net Change In Cash | 3,741 | 25,650 | 10,287 | 47,885 |
Free Cash Flow | -50,001 | -47,625 | -46,993 | -3,580 |
Cash | 110,718 | 67,612 | 93,510 | 109,966 |
Basic Shares | 76,125 | 73,059 | 70,770 | 58,521 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $78,592 | $46,826 | $72,832 | $34,034 |
Gross Profit | -110,489 | 43,849 | 70,435 | -28,071 |
EBITDA | -143,201 | -151,655 | -97,645 | -43,715 |
EBIT | -146,766 | -154,632 | -100,042 | -45,478 |
Net Income | -146,962 | -151,831 | -97,995 | -43,945 |
Net Change In Cash | 78,592 | 46,826 | 72,832 | 34,034 |
Cost of Revenue | 20,433 | 21,499 | -45,196 | |
Free Cash Flow | -137,306 | -155,921 | -130,543 | 79,034 |
Cash | 109,966 | 68,395 | 47,976 | 31,004 |
Basic Shares | 58,365 | 53,933 | 47,989 | 17,349 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.82 |
2024-06-30 | -$0.58 |
2024-03-31 | -$0.62 |
2023-12-31 | -$0.25 |
